SCIENTIFIC-PRACTICAL JOURNAL

| укр | рус |

 

 
Home Editorial ethics For authors Current issue Archive Contacts

No1(4) 2021

Back to the issue


DOI 10.37219/2528-8253-2021-1-56
Gogunska IV, Zabolotna DD, Zaritska LS
Nasafort in the treatment of patients with seasonal allergic rhinitis with sensibilization to weed pollens
Gogunska Inna V.
State Institution “Institute of otolaryngology named after Prof. O.S. Kolomiychenko of the National Academy of Medical Sciences of Ukraine”; Kyiv, Ukraine
Center allergic diseases of the upper respiratory tract
Doctor of Medical Sciences
e-mail: innagogunskaya@gmail.com
ORCID ID: 0000-0001-6952-5057

Zabolotna Diana D.
State Institution “Institute of otolaryngology named after Prof. O.S. Kolomiychenko of the National Academy of Medical Sciences of Ukraine”; Kyiv, Ukraine.
Head of Department of Rhinology and Allergology with a group of radiology
Doctor of Medical Sciences
E-mail: dianazab@ukr.net
ORCID ID: https://orcid.org/0000-0001-7807-8148

Zaritskaya Irina S.
State Institution “Institute of otolaryngology named after Prof. O.S. Kolomiychenko of the National Academy of Medical Sciences of Ukraine”; Kyiv, Ukraine
Department of Inflammatory Diseases of ENT Organs, Leading Researcher
Candidate of Medical Sciences
E-mail: iszar@ukr.net.
ORCIDID: 0000-0002-5109-0996

Abstract

The article presents the results of a study on the use of nasal spray Nazafort allergy protection in the treatment of patients with seasonal allergic rhinitis. The group of patients who used Nazafort in combination with levocetirezine showed a more pronounced and rapid regression of objective and subjective clinical manifestations of the disease compared with the group of patients who received only levocetirizine. The results obtained can be considered as indirect confirmation of the known data on the barrier property of Nazafort in its insufflation in the nasal cavity, which prevents contact of the allergen with the shock organ.

Keywords

seasonal allergic rhinitis, treatment, Nazafort.


Reference

  1. Seidman MD, Gurgel RK, Lin SY, Schwartz SR, Baroody FM, Bonne JR, et al. Guideline Otolaryngology Development
    Group. AAO-HNSF. Clinical practice guideline: allergic rhinitis. Otolaryngol Head Neck Surg. 2015 Feb;152(1 Suppl): S1-43. doi: 10.1177/0194599814561600.
  2. Min YG. The pathophysiology, diagnosis and treatment of allergic rhinitis. Allergy Asthma Immunol Res. 2010 Apr;2(2):65-76. doi: 10.4168/aair.2010.2.2.65.
  3. Mattos JL, Woodard CR, Payne SC. Trends in common rhinologic illnesses: analysis of U.S. healthcare surveys 1995-2007. Int Forum Allergy Rhinol. Jan-Feb 2011;1(1):3-12. doi: 10.1002/alr.20003.
  4. Brożek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines – 2016 revision. J Allergy Clin Immunol. 2017 Oct;140(4):950-958. doi: 10.1016/j.jaci.2017.03.050.
  5. Yurjev SD, Kurchenko AI, Fedoruk GV. [Algorithm of selecting patients with allergic rhinitis and sensitization to house dust mites to conduct allergen immunotherapy]. Immunology and allergology: science and practice. 2019;(1):46-53. [Article in
    Ukrainian].
  6. Zubchenko SО, Yuriev SD. Assessment diagnostic criterion patients with different clinical and laboratory manifestations of sensitization to house dust mites efficiency and forecasting allergen specific immunotherapy based on allergies component diagnostic. Int. Rev. Allergol. Clin. Immunol. Family Med. 2015;21(4):109-16.
  7. Makarenko OV, Solomko DS. Pharmacoeconomic evaluation of allergic rhinitis treatment. Pharmacology and drug toxicology. 2014;39(3):82-7.
  8. Szelenyi I. Allergic rhinitis: meaningful and less meaningful combination treatments including reminiscences. Pharmazie. 2014 Jun;69(6):414-6.
  9. Demoly P, Allaert FA, Lecasble M, Klossek JM, Groupe Pragma. [ERAP, a pharmaco-epidemiologic survey on perennial allergic rhinitis in every day medical practice in France]. Presse Med. 2003 Jun 28;32(23):1066-73. [Article in French].
  10. Demoly P, Allaert FA, Lecasble M, PRAGMA. ERASM, a pharmacoepidemiologic survey on management of intermittent allergic rhinitis in every day general medical practice in France. Allergy. 2002 Jun;57(6):546-54. doi: 10.1034/j.1398-
    9995.2002.t01-1-13370.x.
  11. Allam J-P, Wuestenberg E, Wolf H, Klimek L, Decot E, Horn A, et al. Immunologic response and safety in birch pollen sublingual versus oral vestibule immunotherapy: a pilot study. J Allergy Clin Immunol. 2014 Jun;133(6):1757-9.e3.
    doi: 10.1016/j.jaci.2014.03.026.
  12. de la HozCaballer B, Rodrнguez M, Fraj J, Cerecedo I, Antolнn-Amйrigo D, Colбs C. Allergic rhinitis and its impact on work productivity in primary care practice and a comparison with other common diseases: the Cross-sectional study to evAluate work Productivity in allergic Rhinitis compared with other common dIseases (CAPRI) study. Am J Rhinol Allergy. Sep-Oct
    2012;26(5):390-4. doi: 10.2500/ajra.2012.26.3799.
  13. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008 Apr;63 Suppl 86:8-160. doi: 10.1111/j.1398-9995.2007.01620.x.
  14. Rodinkova VV. [Scientific substantiation of the monitoring and prevention system of the impact of allergenic factors of biological origin on the health of the urban population of Ukraine] [dissertation]. Kiev; 2015. 40 p. [In Ukrainian].
  15. Garib V, Zubchenko S, Chopyak V, Gajewska V, Gajewsky V. [The molecular overview of sensitization to weed pollen allergens and its possible clinical application in ukraine for the optimal allergoimmunotherapy]. Zhurnal vushnyh, nosovyh ta
    gorlovyh hvorob. 2016;(6):28-41. [In Ukrainian].
  16. Bousquet J, Schьnemann HJ, Togias A, Bachert C, Erhola M, Hellings PW, et al. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020 Jan;145(1):70-80.e3.
    doi: 10.1016/j.jaci.2019.06.049.
  17. Unified clinical protocol for primary, secondary (specialized) and tertiary (highly specialized) medical care "Allergic rhinitis". Rinologiya. 2017(3-4):19-43.
  18. Bousquet J, Schunemann HJ, Hellings PW, Arnavielhe S, Bachert C, Bedbrook A, et al. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. J Allergy Clin Immunol. 2016;138(2):367-374.
    doi: 10.1016/j.jaci.2016.03.025.
  19. Ciprandi G, Cirillo IG, Vizzaccaro A, Tosca MA. Levocetirizine improves nasal symptoms and airflow in patients with persistent allergic rhinitis: a pilot study. Eur Ann Allergy Clin Immunol. 2005 Jan;37(1):25-9.
  20. Tarasova GD, Zaitseva OV, Torgovanova EA. [Preventive barrier for allergic rhinitis]. Russian Journal of Allergy. 2012;(2):69-72. [Article in Russian]. doi: https://doi.org/10.36691/RJA745.
  21. Geppe NA, Snogotskaya MN, Konopelko OY. [New in the prevention and treatment of seasonal allergic rhinitis]. Lechaschi Vrach. 2010;(1):39-42. [Article in Ryssian].
  22. A nasally applied cellulose powder in seasonal allergic rhinitis (SAR) in children and adolescents; reduction of symptoms and relation to pollen load Poster presented at EAACI, 2010. Paediatric Allergy and Immunology. 2011;22(1):594-9.
  23. A Nasally Applied Cellulose Powder in Seasonal Allergic Rhinitis in Adults with Grass Pollen Allergy: A Double-Blind, Randomized, PlaceboControlled, Parallel-Group study. International Archives of Allergy and Immunology.2014;
    163(1):313-8.
  24. Inert Cellulose Powder in the Treatment of Seasonal Allergic Rhinitis Journal of Pulmonary &Respiratory Medicine.
    2017;(7):1.
  25. Josling P, Steadman S. Use of Cellulose Powder for the Treatment of Seasonal Allergic Rhinitis. Adv Ther. Jul-Aug 2003;20(4):213-9. doi: 10.1007/BF02850092.
  26. Еberg N, Ospanova S, Nikitin N, Emberlin J, Dahl A. A nasally applied cellulose powder in seasonal allergic rhinitis in adults with grass pollen allergy: a double-blind, randomized, placebo-controlled, parallel-group study. Int Arch Allergy Immunol. 2014;163(4):313-8. doi: 10.1159/000360734.
  27. Minov JB, Karadzinska-Bislimovska J, Petrova T, Vasilevska K, Stoleski S, Mijakoski D. Inert Cellulose Powder in the Treatment of Seasonal Allergic Rhinitis. Journal of Pulmonary & Respiratory Medicine. 2017;(7):1.
  28. Emberlin J.C, Lewis R.A. A double blind, placebo controlled trial of inert cellulose powder for the relief of symptoms of hay fever in adults. Poster presented: World Allergy Congress in Munich 2005. Published: Current Medical Research and Opinion.
    2006;22(2):275-85.
  29. Juniper EF, Stahl E, Doty RL, et al. Clinical outcomes and adverse effect monitoring in allergic rhinitis. J Allergy Clin Immunol. 2005 Mar;115(3 Suppl 1):S390-413. doi: 10.1016/j.jaci.2004.12.014.
  30. Yashina LA, Ignatieva VI. [Possibilities of azelastine in the treatment of seasonal allergic rhinitis in the format of the new study MP4001]. Asthma and allergy. 2013;(1):55-8. [Article in Russian].
 

© 2019, Public Organization «Ukrainian Scientific Medical Society of Otorhinolaryngologists»